Double Medical(SZ:002901) Jing Ji Guan Cha Wang·2026-02-12 07:00Core Viewpoint - The orthopedic industry is facing issues of high sales expenses and shrinking R&D investment, with major companies like Dabo Medical having sales expense ratios above the industry average [1] Group 1: Company Developments - Dabo Medical has recently made a new investment, fully acquiring Maikoste (Xiamen) Medical Equipment Co., Ltd. with a registered capital of 5 million yuan, focusing on professional technical services [1] Group 2: Stock Performance - Dabo Medical's stock price decreased from 50.14 yuan to 48.03 yuan over the past week, reflecting a decline of 2.66% and a volatility of 6.49%; on February 11, the stock fell by 1.58% with a net outflow of 10.377 million yuan [2] - As of February 12, the stock price slightly increased by 0.36% to 48.03 yuan, with a turnover rate of 0.60% and a trading volume of 82.96 million yuan; technical indicators suggest a downward trend [2] Group 3: Financial Performance - Dabo Medical expects a net profit attributable to shareholders for the year 2025 to be between 580 million yuan and 610 million yuan, representing a year-on-year growth of 62.55% to 70.96%; the non-recurring net profit is projected to grow by 59.42% to 69.93% [3] - The primary drivers of this growth are focused on core business, product innovation, and the advancement of international strategies, with a revenue of 1.876 billion yuan in the first three quarters of 2025, marking a year-on-year increase of 22.69% [3] Group 4: Institutional Insights - Institutions predict a net profit growth rate of 50.67% for 2025, with a slowdown to 16.88% in 2026; current institutional ratings are neutral, and the fund holding ratio is low at 0.88%, indicating moderate market attention [4]